Cocrystal Pharma (COCP) Common Equity (2010 - 2026)
Cocrystal Pharma (COCP) posted Common Equity of $4.1 million for Q1 2026, down 34.99% sequentially from $6.3 million in Q4 2025, and down 43.65% YoY from $7.3 million in Q1 2025.
Cocrystal Pharma (COCP) Common Equity (2010 - 2026) Analysis & Trends
Cocrystal Pharma has reported Common Equity for 17 years, with the latest figure at $4.1 million in Q1 2026.
- Quarterly Common Equity fell 43.65% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 43.65% YoY) and the FY2025 annual result came in at $6.3 million, down 33.52% from the prior year.
- Common Equity fell to $4.1 million in Q1 2026 per COCP's latest filing, from $6.3 million in the prior quarter.
- Over five years, Common Equity peaked at $73.6 million in Q1 2022 and troughed at $4.1 million in Q1 2026.
- A 5-year average of $25.4 million and a median of $22.6 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2025: Common Equity surged 41.34% in 2022, then sank 69.33% in 2025.
- Over 5 years, Common Equity stood at $39.6 million in 2022, then slumped by 33.37% to $26.4 million in 2023, then plunged by 63.91% to $9.5 million in 2024, then sank by 33.52% to $6.3 million in 2025, then slumped by 34.99% to $4.1 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $4.1 million, $6.3 million, and $7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.77 Bn | 131.91 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.17 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.60 Bn | 54.47 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 9.79 Bn |
| 10 | Cocrystal Pharma | 16.13 Mn | 13.81 Mn | - | 1.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.04 Mn |
| Mar 31, 2026 | 4.12 Mn |
| Dec 31, 2025 | 6.33 Mn |
| Sep 30, 2025 | 7.67 Mn |
| Jun 30, 2025 | 5.33 Mn |
| Mar 31, 2025 | 7.30 Mn |
| Dec 31, 2024 | 9.52 Mn |
| Sep 30, 2024 | 12.70 Mn |
| Jun 30, 2024 | 17.39 Mn |
| Mar 31, 2024 | 22.59 Mn |
| Dec 31, 2023 | 26.38 Mn |
| Sep 30, 2023 | 30.69 Mn |
| Jun 30, 2023 | 34.68 Mn |
| Mar 31, 2023 | 34.67 Mn |
| Dec 31, 2022 | 39.60 Mn |
| Sep 30, 2022 | 49.91 Mn |
| Jun 30, 2022 | 49.39 Mn |
| Mar 31, 2022 | 73.58 Mn |
| Dec 31, 2021 | 77.55 Mn |
| Sep 30, 2021 | 81.01 Mn |